| 摘要 |
The present invention relates to methods for determining whether a drug candidate should be advanced from discovery through evaluation to development and marketing. In one embodiment of the present invention, the drug development methods utilize a team decision-making format wherein scientific staff, and regulatory, financial, and marketing personnel may contribute to the evaluation of a new drug compound. In another embodiment of the methods of the present invention, decisions concerning the future of a potential drug may be made at earlier designated timepoints in the evaluation process, and these decisions may be made based on criteria such as preclinical pharmacological and toxicological data. In a further embodiment of the present invention, the potential new drug may be assigned a risk characterization, such as a color code, which defines the extent and duration of the evaluation process.
|
